Schedule

Tuesday, Nov. 8, 2022

Pre-Conference Programs

Omni Boston Hotel

Times and program schedules subject to change.


SESSION I
2–3:10 P.M. EST

Using Artificial Intelligence, Machine Learning, and/or Predictive Models to Identify Patients who will most likely Respond to Early Intervention

2 p.m. Introduction
Kald Abdallah, MD, PhD – Bristol Myers Squibb

2:05 p.m. Radiomics, Pathomics, AI for Predicting and Monitoring Treatment Response for Cancer Therapies: Validation on Clinical Trial Datasets  
Anant Madabhushi, PhD – Emory School of Medicine

2:25 p.m. Using Al to Predict Response - Predictive Models with Histology
Antonio Tito Fojo, MD, PhD – Columbia University

2:45 p.m. Panel Discussion
Moderator: Kald Abdallah, MD, PhD – Bristol Myers Squibb
Session I Speakers

3:10 p.m. Break


SESSION II
3:25–5:00 P.M. EST

Using Statistical Models to Refine and Optimize Clinical Trial Design

3:25 p.m. Introduction
Giovanni Melillo, MD AstraZeneca

3:30 p.m. Adapting Radiotherapy to Immune Checkpoint Blockade
Silvia Formenti, MD – Weill Cornell Medicine

3:50 p.m. Integrated Academic Approach and Regulatory/Industry Perspective to Optimize Trial Design for Patient Selection
Tina Cascone, MD, PhD – The University of Texas MD Anderson Cancer Center

4:10 p.m.
Adaptive Phase 2/3 Designs – Time to Hedge
Cong Chen, PhD – Merck

4:30 p.m. Panel Discussion
Moderator: Giovanni Melillo, MD AstraZeneca
Session II Speakers

5:00 p.m. Break


SESSION III
5:10–5:45 P.M. EST

Regulatory Considerations

5:10 p.m. Introduction
Jane Anne Healy, MD – Merck

5:15 p.m. Assessment of Combination Therapies Regarding Safety, Dose, Contribution of Component 

Marc Theoret, MD – Food and Drug Administration (FDA)

5:40 p.m. Concluding Remarks
Jane Anne Healy, MD – Merck

Wednesday, Nov. 9, 2022

Pre-Conference Programs

Omni Boston Hotel

Times and program schedules subject to change.


Primer on Tumor Immunology and Cancer Immunotherapy™

Omni Boston Hotel: 8 A.M.–5 P.M. EST

SESSION I

8:05–9:45 A.M. EST

Introduction to Immunology: Generating Effective Anti-Tumor Immunity

8:05 a.m.

Overview of Innate Immunity in Cancer Immunotherapy and Complexities of Macrophages
Jennifer L. Guerriero, PhD – Brigham and Women’s Hospital

8:25 a.m. Role of Dendritic Cells in Cancer
Niroshana Anandasabapathy, MD, PhD – Weill Cornell Medicine

8:45 a.m. Modeling Adaptive Immune Responses to Cancer in the Mouse
Robert D. Schreiber, PhD, FAIOWashington University School of Medicine

9:05 a.m. B cells and Tertiary Lymphoid Structures in Cancer: What are they Good for?
Tullia C. Bruno, PhD – University of Pittsburgh

9:25 a.m. Session I Panel Discussion
Moderator: Jennifer Guerriero, PhD – Brigham and Women's Hospital
Panelists: Session I Speakers

9:45 a.m.

Break

SESSION II

10–11:45 A.M. EST

Approaches to Immunotherapy: Targeting the Immunosuppressive Tumor Microenvironment

10 a.m. Targeting Tregs in Tumors
Dario Vignali, PhD – University of Pittsburgh

10:20 a.m. The Diversity, Function and Therapeutic Opportunities of Myeloid cells in Cancer
Miriam Merad, MD, PhD – Icahn School of Medicine at Mount Sinai

10:40 a.m. Metabolism in Cancer Immunology and Immunotherapy
Greg Delgoffe, PhD – University of Pittsburgh

11 a.m. Tissue Tension Regulates Myeloid Metabolism to Modulate Tumor Immunity
Valerie Weaver, PhD – University of California San Francisco

11:20 a.m. Session II Panel Discussion
Moderator: Jennifer L. Guerriero, PhD – Brigham and Women’s Hospital
Panelists: Session II Speakers

11:45 a.m.

Lunch

SESSION III
1:15–3 P.M. EST

Approaches to Immunotherapy: Driving T cells to the Tumor

1:15 p.m. Introduction
Sumit K. Subudhi, MD, PhD – The University of Texas MD Anderson Cancer Center


1:20 p.m. Developing Personalized Cancer Vaccines
Catherine Wu, MD – Dana-Farber Cancer Institute and Harvard Medical School

1:40 p.m. Immune Checkpoint Blockade Therapy for Cancer
Sangeeta Goswami, MD, PhD – The University of Texas MD Anderson Cancer Center

2 p.m. Updates in the Science of CAR T cells
Marcela V. Maus, MD, PhD – Massachusetts General Hospital

2:20 p.m. Modulating the Tumor Microenvironment with Bispecifics
Sumit K. Subudhi, MD, PhD – The University of Texas MD Anderson Cancer Center

2:40 p.m. Session III Panel Discussion
Moderator:
Sumit K. Subudhi, MD, PhD – The University of Texas MD Anderson Cancer Center
Panelists: 
Session III Speakers


3 p.m. Break

SESSION IV
3:15–5 P.M. EST

Biomarkers of Response to Immunotherapies

3:15 p.m. Microbiome

Jennifer A. Wargo, MD, MMSc – The University of Texas MD Anderson Cancer Center

3:35 p.m. What You Need for a Good TIME (Tumor Immune MicroEnvironment)
James Gulley, MD, PhD – National Cancer Institute

3:55 p.m. Immune Biomarkers to Guide Clinical Care
Yvonne Saenger, MD – Albert Einstein College of Medicine

4:15 p.m. Current Practical Management and the Future of Personalized Treatment of Immune Related Adverse Events
Julie Brahmer, MD – Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

4:35 p.m. Session IV Panel Discussion
Moderator:
Sumit K. Subudhi, MD, PhD – The University of Texas MD Anderson Cancer Center
Panelists:
Session IV Speakers

4:55 p.m. Closing Remarks
Sumit K. Subudhi, MD, PhD – The University of Texas MD Anderson Cancer Center

SESSION I
9–10:35 A.M. EST

Cellular Targets of Combination Therapies

  Moderator: Zhen Su, MD, MBA – Marengo Therapeutics
9 a.m. Overview
Daniel S. Chen, MD, PhD – Engenuity Life Sciences

9:05 a.m. T Cell Mechanisms
E. John Wherry, PhD – University of Pennsylvania

9:35 a.m. Combination Myeloid cell and T cell Targeting as an Effective Anti-tumor Strategy
Judith A. Varner, PhD University of California, San Diego

10:05 a.m. Implications of Cancer-Associated Fibroblast Heterogeneity for Stroma Targeted Therapies in Solid Tumors 
Ellen Puré, PhD University of Pennsylvania

10:35 a.m. Break

SESSION II
10:45 A.M.–1:45 P.M. EST

Mediators of Immune Inhibition

  Moderator: Philip D. Greenberg, MD, FAIO – Fred Hutchinson Cancer Research Center
10:45 a.m.
Tumor-intrinsic Resistance: Direct Mediators of Immune Escape
Gordon J. Freeman, PhD, FAIODana-Farber Cancer Institute

11:15 a.m. TGF-β Control of Immune Responses in Cancer: a Holistic Immuno-Oncology Perspective

Ming O. Li, PhD – Memorial Sloan Kettering Cancer Center

11:45 a.m. Lunch


1:15 p.m. Co-opting Immune cells to Support Cancer Progression through Metabolic Reprogramming
Susan M. Kaech, PhD – Salk Institute

SESSION III
1:45–3:15 P.M. EST

Immunotherapy Combination Strategies

  Moderator: Daniel S. Chen, MD, PhD – Engenuity Life Sciences
1:45 p.m. Learning from Failure to Identify New Strategies to Expand Checkpoint Blockade Efficacy
Thomas F. Gajewski, MD, PhD – University of Chicago

2:15 p.m. Synthetic Biology in the Age of Cell-Based Immunotherapy
Yvonne Chen, PhD University of California, Los Angeles

2:45 p.m. Orthogonal Combinations - non-IO/IO Combinations
Ira Mellman, PhD – Genentech

3:15 p.m. Break


SESSION IV
3:25–5:30 P.M. EST

Immunotherapy Combination Trial Design

  Moderator: Alexandra Snyder, MD – Generate Biomedicines
3:25 p.m. Application of New Approaches to Study IO Combinations
J. Carl Barrett, PhD – AstraZeneca

3:55 p.m. Combination Therapy - Lessons from Regulatory Submissions
Atiqur Rahman, PhD – Food and Drug Administration-CDER

4:25 p.m. Balancing Speed, Design and Regulatory needs to enable RP2D in Oncology 
Dinesh de Alwis, PhD – Merck Research Labs

4:55 p.m. Sequential vs. Concurrent vs. Phased
Edward Cha, MD, PhD – Genentech

5:25 p.m.
Concluding Remarks

Meet-the-Expert Lunch

Omni Boston Hotel: 11:45 A.M.–1:15 P.M. EST


Grant Writing Workshop

Omni Boston Hotel: 5:45–7:50 P.M. EST

 

SESSION I

5:45–6:55 P.M. EST

GRANT WRITING WORKSHOP


Moderator:
Ravi Patel, MD, PhD  – University of Pittsburgh

5:45 p.m.

Overview Grant Opportunities outside NIH
Christian M. Capitini, MD
University of Wisconsin-Madison

5:55 p.m. NIH Grant Application Strategies
Lillian Kuo, PhD – National Cancer Institute

6:10 p.m. Optimizing your Strategy for Grant Writing
Thomas F. Gajewski, MD, PhD – University of Chicago

6:25 p.m. Principles of Data Sharing
Riyue Bao, PhD – UPMC Hillman Cancer Center

6:40 p.m. Question and Answer


SESSION II

6:55–7:50 P.M. EST

GRANT WRITING WORKSHOP

Moderator: Saman Maleki, PhD Western University

6:55 p.m.

Mock Study Section
Chair:
Thomas F. Gajewski, MD, PhD University of Chicago
Primary Reviewer:
Christian M. Capitini, MD University of Wisconsin-Madison
Scientific Review Officer:
Lillian Kuo, PhD National Cancer Institute
Secondary Reviewer: Ravi Patel, MD, PhD
University of Pittsburgh
Statistical Reviewer: Annette Molinaro, MA, PhD University of California, San Francisco

7:30 p.m. Question and Answer Tables (Various Types of Grants) 
R01– TBD
K08, K99/R00, and other Career Development Awards – Kristin G. Anderson, PhD – Fred Hutchinson Cancer Research Center and Ravi Patel, MD, PhD University of Pittsburgh
Foundation Young Investigator and Clinical Investigator Awards – Abdul Rafeh Naqash, MD Oklahoma University
Fellowships and Career Development Awards for Clinicians
– TBD

Industry Funding: Clinical and Translational Trials Christian M. Capitini, MD – University of Wisconsin-Madison and Saman Maleki, PhD Western University

DOD Grants – Lorenzo Galluzzi, PhD – Weill Cornell Medicine and Claire I. Vanpouille-Box, PhD – Weill Cornell Medicine
F Grants for Graduate Students and Postdocs Nicole E. Scharping, PhD – University of California San Diego


 



7:45 p.m. Concluding Remarks
Rongze O. Lu, PhD University of California, San Francisco

Thursday, Nov. 10, 2022

37th Annual Meeting

Boston Convention & Exhibition Center

9 a.m.–9 p.m. EST

Times and program schedules subject to change.


Session 100

7:40–8 A.M. EST

Presidential Welcome & Awards Ceremony

Location: Hall B2
Chair: Patrick Hwu, MD – Moffitt Cancer Center

 7:40 a.m.

Presidential Welcome

Patrick Hwu, MD – Moffitt Cancer Center

7:45 a.m.

Awards Ceremony 

Patrick Hwu, MD – Moffitt Cancer Center

  • Steven A. Rosenberg, MD, PhD, Scholars Award

  • SITC Fellow of the Academy of Immuno-Oncology (FAIO) Recipients Recognition

  • SITC Lifetime Achievement Award

Session 101

8–8:50 A.M. EST

Richard V. Smalley Memorial Award and Lectureship
A panel honoring the work of Zelig Eshhar, PhD, FAIO

Location: Hall B2
Chair: Patrick Hwu, MD – Moffitt Cancer Center
8 a.m. Introduction and 2022 Richard V. Smalley Memorial Award and Lectureship Recognition

Patrick Hwu, MD – Moffitt Cancer Center

8:05 a.m. Panel Honoring the Work of Zelig Eshhar, PhD
Carl June, MD, FAIOUniversity of Pennsylvania
Crystal Mackall, MD – Stanford University
Steven A. Rosenberg, MD, PhD, FAIONational Cancer Institute
Michel Sadelain, MD, PhD – Memorial Sloan Kettering Cancer Center

8:45 a.m. Question & Answer

8:508:55 a.m. EST

Break

Session 102

8:55–11:05 A.M. EST

Biomarkers

Location: Hall B2
Co-Chairs:
Sacha Gnjatic, PhD – Icahn School of Medicine at Mount Sinai
Kerry L. Reynolds, MD – Massachusetts General Hospital
8:55 a.m. Introduction

9 a.m. CIMAC/SWOG Studies, Effort Funded for IO Biomarkers
Cara Haymaker, PhD – The University of Texas MD Anderson Cancer Center

9:20 a.m. Multi-omic Single-cell Discrimination of Immunotherapy-induced Immune Responses
Lawrence Fong, PhD – University of California San Francisco


9:40 a.m. Role of AF on T Cells; scRNAseq Based Markers
Amy E. Moran, PhD – Oregon Health & Science University

10 a.m. Immune Related Adverse Events
Alexandra-Chloe Villani, PhD – Massachusetts General Hospital


10:20 a.m. Abstract
TBD

10:35 a.m. Panel Discussion

11 a.m. Closing Remarks

11:0511:10 a.m. EST

Break

Session 103

11:10–11:40 A.M. EST

Late Breaking Abstract Session

Location: Hall B2
Co-Chairs: TBD

11:40 A.M.1:10 P.M. EST

Lunch & Poster Viewing

Location: Hall C

Concurrent Session 104

11:55 A.M.–12:55 P.M. EST

Rapid Oral Abstracts - Basic Science

Location: TBD
Co-Chairs: TBD

Concurrent Session 105

11:55 A.M.–12:55 P.M. EST

Rapid Oral Abstracts - Clinical

Location: TBD
Co-chairs: TBD

Concurrent Session 106

11:55 A.M.–12:55 P.M. EST

Integrating Radiation and Immunotherapy for the Treatment of Oligometastatic Disease

Location: TBD
Co-chairs:
Samir N. Khleif, MD - Georgetown University Medical Center
Andrew Sikora, MD, PhD - The University of Texas MD Anderson Cancer Center

11:55 p.m.

Introduction
Samir N. Khleif, MD - Georgetown University Medical Center

12 p.m.

Clinical Opportunities
Mai-Anh Huynh, MD, PhD - Harvard Medical School

12:10 p.m.

Current Challenges that Limit Immunotherapy and How These May Be Overcome by Integrating Radiation Therapy
Fernanda Herrera, MD, PhD - University of Lausanne

12:20 p.m.

Next-Generation Approaches to the Delivering Radiation in Conjunction with Immunotherapy for Patients with Oligometastatic Disease
TBD

12:30 p.m.

Future Directions in the Integration of Radiotherapy and Immunotherapy for Patients with Oligometastatic Disease
Zachary Morris, MD, PhD - University of Wisconsin - Madison

12:40 p.m.

Discussion and Conclusion

Session 107

1:10–2:55 P.M. EST

Immuno-oncology in the Age of Multi-omics: Translating Big Data into Clinical Discoveries

Location: Hall B2
Co-Chairs:
Kellie N. Smith, PhD – Johns Hopkins School of Medicine
Linghua Wang, MD, PhD The University of Texas MD Anderson Cancer Center
1:10 p.m. Multiplex IF Big Data
Janis Taube, MD, MSc – Johns Hopkins School of Medicine

1:30 p.m. Integrative Big Data Approaches for Immuno-oncology
Aaron Newman, PhD - Stanford University

1:50 p.m. Mechanisms of Immunotherapy Resistance
Nir Hacohen, PhD - Massachusetts General Research Institute

2:10 p.m. Abstract

2:25 p.m. Abstract

2:40 p.m. Panel Discussion

2:55–3:20 p.m. EST

Break

Session 1081

3:20–4:30 P.M. EST

Pre-Clinical/Model Systems vs. Human

Location: Hall B2
Co-Chairs:
Elizabeth M. Jaffee, MD, FAIOSidney Kimmel Cancer Center, Johns Hopkins University
Robert D. Schreiber, PhD – Washington University School of Medicine
3:20 p.m. Introduction

3:25 p.m. Combination Vaccine + Checkpoint Immunotherapies
Elizabeth Jaffee, MD, FAIO - Sidney Kimmel Cancer Center, Johns Hopkins University

3:35 p.m. Use of High Dimensional Transcriptomic, Proteomic and Spatial Profiling in Mouse Tumor Models of Cancer Immunotherapy and the Applicability of These Studies to Understanding Naturally Occurring and Therapeutically Induced Human Responses to Cancer
Robert Schreiber, PhD, FAIO - Washington University School of Medicine

3:45 p.m. Cellular Therapies
Philip Greenberg, MD, FAIO - Fred Hutchinson Cancer Research Center

3:55 p.m. Immune Checkpoint/Profiling
A. Karolina Palucka, MD, PhD - The Jackson Laboratory for Genomic Medicine

4:05 p.m. Panel Discussion

4:304:40 p.m. EST

Break

Concurrent Session 108

4:40–5:55 P.M. EST

Immune-Related Adverse Events: Current Status of Research and Paths Forward

Location: TBD
Co-Chairs:
Elad Sharon, MD, MPH – National Cancer Institute
Chloe Villani, PhD – Massachusetts General Hospital
4:40 p.m. Clinical Trials for Immune-Related Adverse Events
Michael Dougan, MD, PhD – Massachusetts General Hospital

5 p.m. Overview of Management of Rare Toxicities and Survivorship
Kerry Reynolds, MD – Massachusetts General Hospital; Harvard Medical School

5:20 p.m. Immune-Mediated Mechanisms in Checkpoint Inhibitor-Induced Myocarditis
Han Zhu, MD – Stanford University

5:40 p.m. Abstract - Translational

Concurrent Session 109

4:40–5:55 P.M. EST

Advances in Imaging Biomarkers, Radiomics, and Artificial Intelligence

Location: TBD
Co-Chairs:
Pedram Heidari, MD – Massachusetts General Hospital
Bachir Taouli, MD – Icahn School of Medicine at Mount Sinai
4:40 p.m. Imaging Response Criteria for Immunotherapy
Lilja Bjork Solnes, MD, MBA – Johns Hopkins Medicine


4:52 p.m. Introduction to Radiomics
Anant Madabhushi, PhD – Case Western Reserve University

5:04 p.m. Radiomics Response to Immunotherapy
Jaileene Perez-Morales, PhD – Moffitt Cancer Center

5:16 p.m. Novel Molecular Imaging Approaches to Assess Immunotherapy Response
Umar Mahmood, MD, PhD – Massachusetts General Hospital


5:28 p.m. Abstract

5:40 p.m. Abstract

5:52 p.m. Closing Remarks

Concurrent Session 110

4:40–5:55 P.M. EST

Bias & Diversity in Cancer Research

Location: TBD
Co-Chairs:
Avery D. Posey, PhD – University of Pennsylvania School of Medicine
Cardinale Smith, MD, PhD – The Tisch Cancer Institute at Mount Sinai
4:40 p.m. Introduction

4:45 p.m. Discuss Access to Immunotherapy Clinical Trials as Well as Community Outreach and Engagement Strategies to Engage Diverse Populations in Trials
Carmen Guerra, MD, MSCE, FACP - Perlman School of Medicine at the University of Pennsylvania

4:45 p.m. Workforce Development and Training
TBD

4:45 p.m. Barriers and Strategies to Increase Clinical Trial Diversity
Barbara Powe, PhD, RN, FAAP - Grail/Illumina

4:45 p.m. Disparities in Treatment and Research
John H. Stewart, IV, MD, MBA, FACS - Louisiana State University

5:50 p.m. Closing Remarks

Concurrent Session 111

4:40–5:55 P.M. EST

Organ-Specific Immune Responses

Location: TBD
Co-Chairs:
Amy B. Heimberger, MD – Northwestern University
Hélène Salmon, PhD – Icahn School of Medicine at Mount Sinai
4:40 p.m. Overview of Field
Hélène Salmon, PhD – Icahn School of Medicine at Mount Sinai

4:50 p.m. Microbiome within Pancreatic Tumors and Impact on Immune Microenvironment
Florencia McAllister, MD – MD Anderson Cancer Center

5:15 p.m. How Adipocytes Influence T Cell Differentiation and Responses
TBD

5:40 p.m. Abstract

5:55 p.m. Closing Remarks

Concurrent Session 112

4:40–5:55 P.M. EST

Cancer Immunogenomics and Immune Response

Location: TBD
Co-Chairs:
Elaine Mardis, PhD – Nationwide Children's Hospital
Charles Swanton, MD, PhD, FRCP – University of London
4:40 p.m. Follow-on Studies on Adult GBM from Multi-Region Sequencing
Elaine Mardis, PhD – Nationwide Children's Hospital

5 p.m. Germline Immune Variants Influence Cancer Risk and Response to Immunotherapy
Hannah Carter, PhD – UC San Diego School of Medicine

5:20 p.m. Single-Cell Multi-Omics Profiling of Tumor Microenvironment and Tumor-Immune Interactions in Gastric Cancer
Linghua Wang, MD, PhD - MD Anderson Cancer Center

5:40 p.m. Abstract

Concurrent Session 113

4:40–5:55 P.M. EST

Cellular Therapies + Bispecifics

Location: TBD
Co-Chairs:
Djordje Atanackovic, MD – University of Maryland Greenebaum Comprehensive Cancer Center
Yvonne Chen, PhD – University of California, Los Angeles
4:40 p.m. Introduction

4:42 p.m. Armored CAR NK Cells
Katy Rezvani, MD, PhD – MD Anderson Cancer Center

5:02 p.m. Bispecific
BiTEs
David Miklos, MD – Stanford University

5:22 p.m. Abstract

5:37 p.m. Abstract

5:52 p.m. Closing Remarks

Concurrent Session 114

4:40–5:55 P.M. EST

Abstract Session

Location: TBD
Co-Chairs: TBD

Concurrent Session 115

4:40–5:55 P.M. EST

Regulatory Subcommittee Session (Part 1)

Location: TBD
Co-Chairs: TBD

5:55–6:05 p.m. EST

Break

Concurrent Session 116

6:05–7:20 P.M. EST

Cancer Immunotherapy in Special Patient Populations

Location: TBD
Co-Chairs:
Crystal Mackall, MD – Stanford University
Keith Sigel, MD, PhD - Icahn School of Medicine at Mount Sinai
6:05 p.m. Immunotherapy for Pediatric Cancer
Paul Sondel, MD, PhD – University of Wisconsin

6:25 p.m. Immunotherapy in Patients with HIV
Elizabeth Chiao, MD, MPH - MD Anderson Cancer Center

6:45 p.m. Immunotherapy in Patients with Autoimmune Diseases
Elad Sharon, MD, MPH – National Cancer Institute

7:05 p.m. Abstract

Concurrent Session 117

6:05–7:20 P.M. EST

Targeting the Tumor and the Immune System: New Combinatorial Strategies

Location: TBD

Co-Chairs:
Sandra Demaria, MD – Weill Cornell Medicine
Raghu Kalluri, MD, PhD – University of Texas MD Anderson Cancer Center
6:05 p.m. Exosomes
Raghu Kalluri, MD, PhD – The University of Texas MD Anderson Cancer Center

6:25 p.m. Integrating Immunotherapy with Breast Cancer Therapeutics
Leisha A. Emens, MD, PhD - UPMC Hillman Cancer Center


6:45 p.m. Rational Selection of Immunotherapy and Radiation Therapy Combinations
Sandra Demaria, MD - Weill Cornell Medicine

7:05 p.m. Abstract

Concurrent Session 118

6:05–7:20 P.M. EST

Microbiome, Diet, and Cancer Immunotherapy

Location: TBD
Co-Chairs:
Thomas F. Gajewski, MD, PhD – University of Chicago
Jennifer L. McQuade, MD – University of Texas MD Anderson Cancer Center
6:05 p.m. Gut Microbiota Influence on Anti-tumor Immunity Via Regulation of Myeloid Cells 
Thomas Gajewski, MD, PhD – University of Chicago

6:25 p.m. Diet, Ongoing Interventional Studies
Jennifer McQuade, MD – University of Texas MD Anderson Cancer Center

6:45 p.m. Fecal Microbiota Transplantation and Cancer Immunotherapy
Gal Market, MD – Rabin Medical Center, Israel

7:05 p.m. Abstract

Concurrent Session 119

6:05–7:20 P.M. EST

Vaccines: in Situ Agents and Novel Systemic Approaches

Location: TBD
Co-Chairs:
Ann W. Silk, MD, MS – Dana-Farber Cancer Institute
Dmitry Zamarin, MD, PhD – Memorial Sloan Kettering
6:05 p.m. Introduction

6:10 p.m. Oncolytic Viral Therapy - Beyond the 1st Generation
Igor Puzanov, MD, MSCI, FACP – Roswell Park Comprehensive Cancer Center

6:25 p.m. Utilizing Tumor Microenvironment Antigens for Immune Modulatory Vaccines
Mads Hald Andersen, PhD – Herlev and Gentofte Hospital

6:40 p.m. Abstract

6:50 p.m. Abstract

7 p.m. Abstract

7:10 p.m. Panel Discussion

Concurrent Session 120

6:05–7:20 P.M. EST

Tertiary Lymphoid Structures

Location: TBD
Co-Chairs:
Haydn Kissick, PhD – Emory University
Catherine Sautes-Fridman, PhD – Centre de Recherche des Cordeliers
6:05 p.m. Recent Breakthroughs in TLS Field 
Catherine Sautes- Fridman, PhD – Centre de Recherche des Cordeliers

6:15 p.m. Cellular Composition of TCF1+ CD8 T-cell Immune Neighborhoods in Human Cancers
Haydn Kissick, PhD – Emory University

6:25 p.m. Cellular and Molecular Mechanisms Driving Development of Tertiary Lymphoid Structures in Cancer
Victor Engelhard, PhD – University of Virginia

6:45 p.m. Multifaceted Anti-tumor Effects of Intra-tumoral Tertiary Lymphoid Structures are Driven by Tfh Cells
Jose Conejo-Garcia, MD, PhD – Moffitt Cancer Center

7:05 p.m. Abstract

Concurrent Session 121

6:05–7:20 P.M. EST

Clinical Development of Novel Checkpoint Inhibitors

Location: TBD
Co-Chairs:
Hussein A. Tawbi, MD, PhD – The University of Texas MD Anderson Cancer Center
Hassane M. Zarour, MD – UPMC Hillman Cancer Center
6:05 p.m. Introduction

6:10 p.m. The Emergence of LAG3-Blockade & Opportunities for Future Development
Hussein A. Tawbi, MD, PhD – The University of Texas MD Anderson Cancer Center

6:30 p.m. Abstract

6:45 p.m. Abstract

7 p.m. Abstract

7:15 p.m. Closing Remarks

Concurrent Session 122

6:05–7:20 P.M. EST

Abstract Session

Location: TBD
Co-Chairs: TBD

Concurrent Session 123

6:05–7:20 P.M. EST

Regulatory Subcommittee Session (Part 2)

Location: TBD
Co-Chairs: TBD

7:20-7:30 p.m. EST

Break

7:30–9 P.M. EST

Poster Reception and Meet the Fellows (FAIO) Event

Location: Hall C

Friday, Nov. 11, 2022

37th Annual Meeting

Boston Convention & Exhibition Center

9 a.m.–8:30 p.m. EST

Times and program schedules subject to change.


Session 200
7:15–7:45 A.M. EST

SITC Business Meeting

Location: Hall B2
Chair: TBD

Session 201

8–8:20 A.M. EST

Organizer Welcome & Awards Ceremony

Location: Hall B2
Chair: TBD
8 a.m. Organizer Welcome

8:05 a.m.

Awards Ceremony
Patrick Hwu, MD – Moffitt Cancer Center

  • Tara Withington Public Service Award

  • Pedro J. Romero Service to JITC Award

  • JITC Best Paper Awards

Session 202

8:20–9:10 A.M. EST

Keynote Address

Location: Hall B2
Co-Chair: Patrick Hwu, MD – Moffitt Cancer Center
8:20 a.m. Introduction

8:25 a.m. From the Clinic to the Lab: Investigating Mechanisms of Response and Resistance to Immune Checkpoint Therapy
Padmanee Sharma, MD, PhD – The University of Texas MD Anderson Cancer Center

9:05 a.m. Question & Answer
Padmanee Sharma, MD, PhD – The University of Texas MD Anderson Cancer Center

9:10–9:35 a.m. EST

Break

Session 203

9:35–11:20 A.M. EST

Immunotherapy in Early Stage Disease

Location: Hall B2
Co-Chairs:
Matthew D. Galsky, MD – Tisch Cancer Institute At Mount Sinai Medical Center (GU)
Elizabeth A. Mittendorf, MD, PhD – Dana-Farber Cancer Institute Brigham & Women's Cancer Institute
9:35 a.m. Why the Neoadjuvant Setting?
Myriam Chalabi, MD The Netherlands Cancer Institute

10 a.m. Neoadjuvant Studies to Dissect Mechanisms Underlying Treatment Response and Resistance 
Tina Cascone, MD, PhD – The University of Texas MD Anderson Cancer Center

10:25 a.m. Pathologic Assessment of Tissues, Planning of Treatments, Histopathology
Janis Taube, MD, MSc Johns Hopkins School of Medicine

10:50 a.m. Abstract

11:05 a.m. Abstract

11:20–11:25 a.m. EST

Break

Session 204

11:25–11:55 A.M. EST

Late Breaking Abstract Session

Location: Hall B2
Co-Chairs: TBD

11:55 a.m.-1:25 p.m. EST

Lunch & Poster Viewing

Location: Hall C

Concurrent Session 205

12:10–1:10 P.M. EST

Rapid Oral Abstracts - Basic Science

Location: TBD
Co-Chairs: TBD

Concurrent Session 206

12:10–1:10 P.M. EST

Rapid Oral Abstracts - Clinical

Location: TBD
Co-Chairs: TBD

Concurrent Session 207

12:10–1:10 P.M. EST

A Look at JITC's High-Impact Science

Location: TBD
Co-Chairs:
James L. Gulley, MD, PhD, FACP – National Cancer Institute
Pedro J. Romero, MD – Lausanne Branch, Ludwig Institute for Cancer Research

 12:10 p.m.

Introduction
Pedro J. Romero, MD – Lausanne Branch, Ludwig Institute for Cancer Research

 12:15 p.m.

Understanding Journal and Article Metrics: How to Valuate Them
Pedro J. Romero, MD – Lausanne Branch, Ludwig Institute for Cancer Research

 12:20 p.m.

TBD

 12:25 p.m.

TBD

 12:30 p.m.

TBD

 12:35 p.m.

TBD

 12:40 p.m.

TBD

 12:45 p.m.

JITC: The Next 10 Years
James L. Gulley, MD, PhD, FACP – National Cancer Institute

 12:55 p.m.

Q&A

Session 208

1:25–2:50 P.M. EST

Presidential Session

Location: Hall B2
Co-Chair: Patrick Hwu, MD – Moffitt Cancer Center

2:50–2:55 p.m. EST

Break

Session 209

2:55–4:05 P.M. EST

Survival Data in Adjuvant Setting; Analysis of Benefits (Debate)

Location: Hall B2
Co-Chairs:
Caroline Robert, MD, PhD - Institut Gustave Roussy
Thomas Powles, MBBS, MD, MRCP - Queen Mary University of London

2:55 p.m.

Adjuvant Therapy in Melanoma
Caroline Robert, MD PhD - Institut Gustave Roussy

3:02 p.m.

Adjuvant Therapy in Renal and Bladder Cancers
Thomas Powles, MBBS, MD, MRCP - Queen Mary University of London

3:09 p.m.

Adjuvant Therapy in Breast Cancer
TBD

3:16 p.m.

Neoadjuvant vs Adjuvant Immunotherapy for Resectable NSCLC
John Heymach, MD, PhD - University of Texas MD Anderson Cancer Center

3:23 p.m.

Economics of Adjuvant Therapy
TBD

3:33 p.m.

Q&A

3:48 p.m.

Debate for and Against Adjuvant Therapy

4:05–4:20 p.m. EST

Break

Concurrent Session 210

4:20–5:35 P.M. EST

Cancer Surgery in the Age of immunotherapy

Location: TBD
Co-Chairs:
Genevieve M. Boland, MD, PhD – Massachusetts General Hospital
Myron E. Schwartz, MD – Mount Sinai School of Medicine
4:20 p.m. Integrating Imaging and Tissue-Based Analysis to Unravel Treatment Response and Resistance Mechanisms in Melanoma
Ashley Holder, MD – University of Alabama at Birmingham

4:40 p.m. The Expanding Role of Surgery in Stage IV Melanoma
Michael Lowe, MD, MA – Emory University School of Medicine

5 p.m. Neoadjuvant program –Surgeon’s Perspective
Integration of Radiation in Neoadjuvant Therapy
John Sfakianos, MD – Icahn School of Medicine at Mount Sinai

5:20 p.m. Abstract

Concurrent Session 211

4:20–5:35 P.M. EST

Extended Analysis of the Tumor Microenvironment: Beyond Tumor and Immune Cells

Location: TBD
Co-Chairs:
Peter S. Nelson, MD – Fred Hutchinson Cancer Research Center
Janis M. Taube, MD, MSc – Johns Hopkins School of Medicine
4:20 p.m. Technology Development; Spatial Imaging
Peter Sorger, PhD – Harvard Medical School

4:40 p.m. Senescence –Therapeutic-Induced; Ageing
Jennifer Elisseeff, PhD – Johns Hopkins School of Medicine

5 p.m. Lymphatic Transport, Lymph Node Metastasis, and Immunity
Amanda Lund, PhD – NYU Grossman School of Medicine

5:20 p.m. Abstract

Concurrent Session 212

4:20–5:35 P.M. EST

Next Generation Checkpoint Blockade: Mechanisms of Action

Location: TBD
Co-Chairs:
Ana Carrizosa Anderson, PhD – Harvard Medical School
Ira Mellman, PhD – Genentech
4:20 p.m. Temporal Single-cell Profiling Identifies B-cell Specific Checkpoint Molecules that Regulate Anti-tumor Immunity
Vijay Kuchroo, DVM, PhD – Harvard Medical School

4:40 p.m. Mechanisms of Tim-3 Inhibition
Ana Carrizosa Anderson, PhD - Harvard Medical School

5 p.m. TIGIT Mechanism of Action
Ira Mellman, PhD - Genentech

5:20 p.m. Abstract

Concurrent Session 213

4:20–5:35 P.M. EST

Next-Generation Cytokine Therapy

Location: TBD
Co-Chairs:
Kim A. Margolin, MD – St. John’s Cancer Institute
Aaron M. Ring, MD, PhD – Yale University School of Medicine
4:20 p.m. Tumor-targeted Delivery of Immunostimulatory Cytokine/Antibody Fusion Proteins
Jamie Spangler, PhD – Johns Hopkins

4:40 p.m. New Data on IL-18, an Innate Cytokine
Aaron Ring, MD, PhD – Yale School of Medicine

5 p.m. Plasticity of Cells in Presence of Different Cytokines
Andy Minn, MD, PhD - University of Pennsylvania

5:20 p.m. Abstract

Concurrent Session 214

4:20–5:35 P.M. EST

Abstract Session

Location: TBD
Co-Chairs: TBD

5:35–5:40 p.m. EST

Break

Session 215

5:40–6:25 P.M. EST

Poster Symposium

Location: TBD
Co-Chairs: TBD

6:25–6:30 p.m. EST

Break

6:30–7 P.M. EST

Awards Ceremony

Location: Hall B2
Chair: Patrick Hwu, MD – Moffitt Cancer Center

 

  • Young Investigator Awards
  • Martin "Mac" Cheever Excellence in Clinical Trial Design - Travel Award
  • SITC Fellowship and Technology Awards
  • Connect-a-Colleague Top Referrer
  • Sparkathon Class of 2022 Recognition
  • Presidential Travel Awards
  • Presidential Award

7–8:30 P.M. EST

Poster Reception and JITC 10th Anniversary Celebration Reception

Location: Hall C 

8:30–11:30 P.M. EST

The CheckPoints Party

Location: TBD



Saturday, Nov. 12, 2022

37th Annual Meeting

Boston Convention & Exhibition Center

8 a.m.–1:05 p.m. EST

Times and program schedules subject to change.


Session 300

8–8:05 A.M. EST

Organizer Welcome

Location: Hall B2
Chair:

Session 301

8:05–9:45 A.M. EST

Resistance to Checkpoint Blockade Immunotherapy

Location: Hall B2
Co-Chairs:
Padmanee Sharma, MD, PhD – The University of Texas MD Anderson Cancer Center
Alexandra Snyder, MD – Generate Biomedicines
8:05 a.m. Introduction

8:10 a.m. Myeloid Cells; Angiogenesis and Hypoxia
Stefani Spranger, PhD - Ludwig Center – Massachusetts Institute of Technology

8:35 a.m. Patterns of Progression and Response: Tumor Dynamics in Patients Treated with CPI Beyond Progression
Alexandra Snyder, MD – Generate Biomedicines

9 a.m. Abstract

9:15 a.m. Models and Mechanisms of Resistance to Immune Checkpoint Blockade in Lung Cancer
Katerina Politi, PhD – Yale School of Medicine

9:40 a.m. Closing Remarks

9:45–9:55 A.M. EST

Break

Session 302

9:55–11:25 A.M. EST

Thomas Waldmann Memorial Plenary Session: New Immunotherapies

Location: Hall B2
Co-Chairs:
Andrea Schietinger, PhD – Memorial Sloan Kettering Cancer Center
Ryan J. Sullivan, MD – Harvard Medical School, Massachusetts General Hospital
9:55 a.m. Introduction

10 a.m. LAG-3
Dario Vignali, PhD – University of Pittsburgh School of Medicine

10:20 a.m. Library-based Approaches to Detect and Reprogram Immunity
Michael Birnbaum, PhD – Massachusetts Institute of Technology

10:40 a.m. Abstract

10:50 a.m. Abstract

11 a.m. Q&A and Closing Remarks

11:25–11:35 A.M. EST

Break

Session 303

11:35–1:05 P.M. EST

Hot Topic Symposium

Location: Hall B2
Co-Chairs: TBD